Hanqing Hu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Hanqing Hu has a total of 45 co-authors. Here are the top co-authors by number of shared publications:
Chunlin Wang
Department of Colorectal Cancer Surgery The Second Affiliated Hospital of Harbin Medical University Harbin Heilongjiang P. R. China
3 shared publicationsYuliuming Wang
Department of Colorectal Cancer Surgery The Second Affiliated Hospital of Harbin Medical University Harbin Heilongjiang P. R. China
3 shared publicationsYunxiao Liu
Department of Colorectal Cancer Surgery The Second Affiliated Hospital of Harbin Medical University Harbin Heilongjiang P. R. China
3 shared publications- Guiyu Wang
Department of Colorectal Surgery The Second Affiliated Hospital of Harbin Medical University Harbin China
2 shared publications - Guiyu Wang
Department of Colorectal Tumor Surgery, Second Affiliated Hospital of Harbin Medical University, Harbin, China
2 shared publications Hao Zhang
Department of Colorectal Cancer Surgery The Second Affiliated Hospital of Harbin Medical University Harbin Heilongjiang P. R. China
2 shared publications
Latest Publications
- Open Access
- 19 May 2026
- Published by Wiley in Advanced Science
- Vol. 13 (45) , e75758
Aptamer‐Targeted PrPC Drives Colorectal Cancer Metastasis via a LYN‐STAT3 Complex and Enables Liquid Biopsy Detection
Colorectal cancer (CRC) poses a significant global health challenge, highlighting the need for better diagnostic tools and molecular targets. Compared to traditional antibodies, aptamers, which are single‐stranded oligonucleotides with high affinity and low immunogenicity, offer an ideal platform for discovering novel biomarkers. Based on this approach, we used the Cell‐SELEX strategy to develop a high‐affinity aptamer‐based probe, WHY‐3E, which successfully identified the cellular prion protein (PrPC) as a key molecular target. We observed that PrPC was significantly upregulated in CRC tissues, strongly correlating with unfavorable clinical outcomes. Functionally, PrPC promotes malignant phenotypes, including migration and invasion, by regulating MSN. Mechanistically, we revealed that PrPC physically translocates from the cell surface to the cytoplasm via endocytosis. Once internalized, it interacts with the STAT3‐NTD and LYN‐SH domains, facilitating the ternary complex formation that enhances LYN‐mediated STAT3 phosphorylation, ultimately increasing MSN transcriptional activity. Moreover, the deubiquitinase USP18 stabilizes PrPC by removing its Lys48‐linked ubiquitin chains, ensuring the continuous activation of this oncogenic axis. Notably, the WHY‐3E aptamer achieved 90.6% sensitivity and 89.0% specificity in detecting PrPC‐positive circulating exosomes in patient cohorts. These findings deepen the mechanistic understanding of CRC progression and offer novel strategic avenues for PrPC‐targeted aptamer applications in non‐invasive diagnostics.
- 19 May 2026
- Published by Wiley in Advanced Science
- Vol. 13 (45) , e75758
Open AccessAptamer‐Targeted PrPC Drives Colorectal Cancer Metastasis via a LYN‐STAT3 Complex and Enables Liquid Biopsy Detection
Colorectal cancer (CRC) poses a significant global health challenge, highlighting the need for better diagnostic tools and molecular targets. Compared to traditional antibodies, aptamers, which are single‐stranded oligonucleotides with high affinity and low immunogenicity, offer an ideal platform for discovering novel biomarkers. Based on this approach, we used the Cell‐SELEX strategy to develop a high‐affinity aptamer‐based probe, WHY‐3E, which successfully identified the cellular prion protein (PrPC) as a key molecular target. We observed that PrPC was significantly upregulated in CRC tissues, strongly correlating with unfavorable clinical outcomes. Functionally, PrPC promotes malignant phenotypes, including migration and invasion, by regulating MSN. Mechanistically, we revealed that PrPC physically translocates from the cell surface to the cytoplasm via endocytosis. Once internalized, it interacts with the STAT3‐NTD and LYN‐SH domains, facilitating the ternary complex formation that enhances LYN‐mediated STAT3 phosphorylation, ultimately increasing MSN transcriptional activity. Moreover, the deubiquitinase USP18 stabilizes PrPC by removing its Lys48‐linked ubiquitin chains, ensuring the continuous activation of this oncogenic axis. Notably, the WHY‐3E aptamer achieved 90.6% sensitivity and 89.0% specificity in detecting PrPC‐positive circulating exosomes in patient cohorts. These findings deepen the mechanistic understanding of CRC progression and offer novel strategic avenues for PrPC‐targeted aptamer applications in non‐invasive diagnostics.
- Open Access
- 1 May 2025
- Published by Taylor & Francis in Advances in Medical Education and Practice
- Vol. ume 16, 849-860
Enhancing Teamwork and Clinical Competence in Radiotherapy Education: Integrating TeamSTEPPS with PEARLS Structured Debriefing in Scenario-Based Simulations
Objective: This study aimed to evaluate whether integrating the TeamSTEPPS model with PEARLS structured debriefing improves teamwork competencies and clinical decision-making among radiotherapy residents, compared to traditional simulation teaching, and to assess its broader applicability in medical education. Methods: From June to December 2023, 36 standardized training residents from the Radiotherapy Department of Harbin Medical University Cancer Hospital were selected and randomly assigned to an experimental group and a control group, each with 18 participants, using a random number table The experimental group underwent scenario-based simulation teaching incorporating the TeamSTEPPS model and PEARLS structured debriefing, while the control group received traditional simulation teaching. Post-intervention, a unified quantitative assessment evaluated theoretical knowledge, skill performance, and simulation performance in both groups. Additionally, satisfaction levels were assessed via questionnaire. Results: The experimental group exhibited significantly higher scores in theoretical knowledge (88.55± 6.52) and skill performance (87.68± 18.42) compared to the control group (71.63± 5.69 and 58.96± 11.47, respectively; P< 0.05). The experimental group exhibited statistically significant improvements in teamwork competencies, including communication (23.22± 2.21 vs 21.43± 3.77, P< 0.05), leadership (23.40± 2.22 vs 22.19± 3.51, P< 0.05), situational awareness (18.95± 1.61 vs 17.62± 2.64, P< 0.05), and mutual support (27.93± 2.92 vs 25.69± 5.76, P< 0.05). The experimental group’s higher satisfaction (94.44% vs 77.78%, P< 0.05) underscores the potential of this integrated approach to address systemic challenges in clinical education, such as fragmented teamwork training and insufficient reflective practice. These findings suggest that combining TeamSTEPPS with PEARLS could serve as a replicable framework for multidisciplinary medical training programs aiming to enhance both technical proficiency and collaborative care. Conclusion: The innovative combined teaching method applied in this study to scenario-based simulation teaching in radiation oncology can significantly enhance residents’ theoretical knowledge, skill performance, and team collaboration abilities.This methodology exhibits notable advantages in clinical teaching within the radiotherapy department and with potential applicability to multidisciplinary medical education and standardized residency programs.
- 1 May 2025
- Published by Taylor & Francis in Advances in Medical Education and Practice
- Vol. ume 16, 849-860
Open AccessEnhancing Teamwork and Clinical Competence in Radiotherapy Education: Integrating TeamSTEPPS with PEARLS Structured Debriefing in Scenario-Based Simulations
Objective: This study aimed to evaluate whether integrating the TeamSTEPPS model with PEARLS structured debriefing improves teamwork competencies and clinical decision-making among radiotherapy residents, compared to traditional simulation teaching, and to assess its broader applicability in medical education. Methods: From June to December 2023, 36 standardized training residents from the Radiotherapy Department of Harbin Medical University Cancer Hospital were selected and randomly assigned to an experimental group and a control group, each with 18 participants, using a random number table The experimental group underwent scenario-based simulation teaching incorporating the TeamSTEPPS model and PEARLS structured debriefing, while the control group received traditional simulation teaching. Post-intervention, a unified quantitative assessment evaluated theoretical knowledge, skill performance, and simulation performance in both groups. Additionally, satisfaction levels were assessed via questionnaire. Results: The experimental group exhibited significantly higher scores in theoretical knowledge (88.55± 6.52) and skill performance (87.68± 18.42) compared to the control group (71.63± 5.69 and 58.96± 11.47, respectively; P< 0.05). The experimental group exhibited statistically significant improvements in teamwork competencies, including communication (23.22± 2.21 vs 21.43± 3.77, P< 0.05), leadership (23.40± 2.22 vs 22.19± 3.51, P< 0.05), situational awareness (18.95± 1.61 vs 17.62± 2.64, P< 0.05), and mutual support (27.93± 2.92 vs 25.69± 5.76, P< 0.05). The experimental group’s higher satisfaction (94.44% vs 77.78%, P< 0.05) underscores the potential of this integrated approach to address systemic challenges in clinical education, such as fragmented teamwork training and insufficient reflective practice. These findings suggest that combining TeamSTEPPS with PEARLS could serve as a replicable framework for multidisciplinary medical training programs aiming to enhance both technical proficiency and collaborative care. Conclusion: The innovative combined teaching method applied in this study to scenario-based simulation teaching in radiation oncology can significantly enhance residents’ theoretical knowledge, skill performance, and team collaboration abilities.This methodology exhibits notable advantages in clinical teaching within the radiotherapy department and with potential applicability to multidisciplinary medical education and standardized residency programs.
- Open Access
- 12 February 2025
- Published by Springer Nature in Discover Oncology
- Vol. 16 (1) , 1-20
Identification of T cell dysfunction molecular subtypes and exploration of potential immunotherapy targets in BRAF V600E-mutant colorectal cancer
Background: Immunotherapy is an effective treatment for BRAF V600E-mutant colorectal cancer, but currently, only a few benefit from it. Therefore, exploring new immunotherapy strategies is essential. Methods: We obtained RNA sequencing data and clinical information of colorectal cancer patients from the TCGA and GEO databases. The impact of the BRAF V600E mutation on tumor microenvironment characteristics, gene expression, and signaling pathways was evaluated using bioinformatics approaches. Weighted gene co-expression network analysis (WGCNA) were used to identify core genes associated with T cell dysfunction. Consensus clustering was applied for subtype construction. Least Absolute Shrinkage and Selection Operator (LASSO) and Random Forest (RF) algorithms were employed to filter potential immunotherapy targets. Results: We found that BRAF V600E mutation has a complex impact on the immune profile of colorectal cancer. It increases immune cell infiltration and activates immune-related signaling pathways, yet it also severely restricts T cell function. We subsequently identified 39 core genes associated with T cell dysfunction and constructed subtypes of BRAF V600E colorectal cancer based on their expression profiles. Significant heterogeneity was observed between these subtypes in immune signaling pathway activity, immune infiltration patterns, immune phenotype scores, and mechanisms of resistance to immunotherapy. Ultimately, using machine learning algorithms and bioinformatics validation, we identified IDO1 as a potential immunotherapy targets for BRAF V600E-mutant colorectal cancer. Conclusion: This study constructed novel T cell dysfunction molecular subtypes for BRAF V600E-mutant colorectal cancer and identified IDO1 as a potential immunotherapy target, providing a new strategy for immunotherapy.
- 12 February 2025
- Published by Springer Nature in Discover Oncology
- Vol. 16 (1) , 1-20
Open AccessIdentification of T cell dysfunction molecular subtypes and exploration of potential immunotherapy targets in BRAF V600E-mutant colorectal cancer
Background: Immunotherapy is an effective treatment for BRAF V600E-mutant colorectal cancer, but currently, only a few benefit from it. Therefore, exploring new immunotherapy strategies is essential. Methods: We obtained RNA sequencing data and clinical information of colorectal cancer patients from the TCGA and GEO databases. The impact of the BRAF V600E mutation on tumor microenvironment characteristics, gene expression, and signaling pathways was evaluated using bioinformatics approaches. Weighted gene co-expression network analysis (WGCNA) were used to identify core genes associated with T cell dysfunction. Consensus clustering was applied for subtype construction. Least Absolute Shrinkage and Selection Operator (LASSO) and Random Forest (RF) algorithms were employed to filter potential immunotherapy targets. Results: We found that BRAF V600E mutation has a complex impact on the immune profile of colorectal cancer. It increases immune cell infiltration and activates immune-related signaling pathways, yet it also severely restricts T cell function. We subsequently identified 39 core genes associated with T cell dysfunction and constructed subtypes of BRAF V600E colorectal cancer based on their expression profiles. Significant heterogeneity was observed between these subtypes in immune signaling pathway activity, immune infiltration patterns, immune phenotype scores, and mechanisms of resistance to immunotherapy. Ultimately, using machine learning algorithms and bioinformatics validation, we identified IDO1 as a potential immunotherapy targets for BRAF V600E-mutant colorectal cancer. Conclusion: This study constructed novel T cell dysfunction molecular subtypes for BRAF V600E-mutant colorectal cancer and identified IDO1 as a potential immunotherapy target, providing a new strategy for immunotherapy.
- Open Access
- 7 June 2024
- Published by Wiley in Clinical and Translational Medicine
- Vol. 14 (6) , e1730
SKA3/PTTG1/c‐MYC signal loop drives the progression of colorectal cancer
- 7 June 2024
- Published by Wiley in Clinical and Translational Medicine
- Vol. 14 (6) , e1730
Open AccessSKA3/PTTG1/c‐MYC signal loop drives the progression of colorectal cancer
- Open Access
- 22 August 2023
- Published by Austin Publishing Group in Annals of Hematology & Oncology
- Vol. 10 (5)
A Case of Synchronous Rectal Cancer and Right Sided Colon Cancer Treated with Transvaginal NOSES Technique
Introduction: We reported a 53 years old female patient with synchronous rectal cancer and right sided colon cancer who underwent transvaginal NOSES to resect two tumors with no serious postoperative complications.
- 22 August 2023
- Published by Austin Publishing Group in Annals of Hematology & Oncology
- Vol. 10 (5)
Open AccessA Case of Synchronous Rectal Cancer and Right Sided Colon Cancer Treated with Transvaginal NOSES Technique
Introduction: We reported a 53 years old female patient with synchronous rectal cancer and right sided colon cancer who underwent transvaginal NOSES to resect two tumors with no serious postoperative complications.
- Open Access
- 18 April 2023
- Published by Spandidos Publications in Oncology Letters
- Vol. 25 (6) , 1-13
Molecular subtyping in colorectal cancer: A bridge to personalized therapy (Review)
Colorectal cancer (CRC) is a malignant tumor and a major cause of morbidity and mortality globally. The classic Tumor‑Node‑Metastasis staging system, which currently underlies the diagnosis and treatment of CRC, is primarily a ‘one drug fits all’ model for patients exhibiting the same pathological features. However, a high degree of variability has been established in the long‑term survival outcomes of patients with CRC with similar pathological types and stages, which can be partially attributed to tumor‑specific molecular biology to some extent. Molecular classification of CRC can further assist with understanding the biological behavior of tumor genesis, development and prognosis, and assist clinicians in improving or customizing the treatment strategy of CRC. In the present study, clinical studies carried out to date are reviewed, and their clinical value is discussed. A multilevel overview of the major molecular types of CRC is provided, in the hope that investigators are encouraged to combine multiple omics studies for interrogating cancer.
- 18 April 2023
- Published by Spandidos Publications in Oncology Letters
- Vol. 25 (6) , 1-13
Open AccessMolecular subtyping in colorectal cancer: A bridge to personalized therapy (Review)
Colorectal cancer (CRC) is a malignant tumor and a major cause of morbidity and mortality globally. The classic Tumor‑Node‑Metastasis staging system, which currently underlies the diagnosis and treatment of CRC, is primarily a ‘one drug fits all’ model for patients exhibiting the same pathological features. However, a high degree of variability has been established in the long‑term survival outcomes of patients with CRC with similar pathological types and stages, which can be partially attributed to tumor‑specific molecular biology to some extent. Molecular classification of CRC can further assist with understanding the biological behavior of tumor genesis, development and prognosis, and assist clinicians in improving or customizing the treatment strategy of CRC. In the present study, clinical studies carried out to date are reviewed, and their clinical value is discussed. A multilevel overview of the major molecular types of CRC is provided, in the hope that investigators are encouraged to combine multiple omics studies for interrogating cancer.